DE69838334D1 - Kdr, ein menschlicher tyrosin kinase rezeptor - Google Patents

Kdr, ein menschlicher tyrosin kinase rezeptor

Info

Publication number
DE69838334D1
DE69838334D1 DE69838334T DE69838334T DE69838334D1 DE 69838334 D1 DE69838334 D1 DE 69838334D1 DE 69838334 T DE69838334 T DE 69838334T DE 69838334 T DE69838334 T DE 69838334T DE 69838334 D1 DE69838334 D1 DE 69838334D1
Authority
DE
Germany
Prior art keywords
kdr
tyrosine kinase
kinase receptor
human
human tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69838334T
Other languages
English (en)
Other versions
DE69838334T2 (de
Inventor
Richard L Kendall
Kenneth A Thomas
Xianzhi Mao
Andrew Tebben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21968566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69838334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69838334D1 publication Critical patent/DE69838334D1/de
Publication of DE69838334T2 publication Critical patent/DE69838334T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69838334T 1997-06-18 1998-06-17 Kdr, ein menschlicher tyrosin kinase rezeptor Revoked DE69838334T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5096297P 1997-06-18 1997-06-18
US50962P 1997-06-18
PCT/US1998/012569 WO1998058053A1 (en) 1997-06-18 1998-06-17 Human receptor tyrosine kinase, kdr

Publications (2)

Publication Number Publication Date
DE69838334D1 true DE69838334D1 (de) 2007-10-11
DE69838334T2 DE69838334T2 (de) 2008-06-12

Family

ID=21968566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838334T Revoked DE69838334T2 (de) 1997-06-18 1998-06-17 Kdr, ein menschlicher tyrosin kinase rezeptor

Country Status (8)

Country Link
US (4) US6204011B1 (de)
EP (1) EP1009814B1 (de)
JP (1) JP4405597B2 (de)
AT (1) ATE371727T1 (de)
CA (1) CA2293723A1 (de)
DE (1) DE69838334T2 (de)
ES (1) ES2292204T3 (de)
WO (1) WO1998058053A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
EP1037981A1 (de) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Lösliche inhibitoren des vaskularen endothelialen wachstumsfaktors, und verwendung davon
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
AU1908000A (en) * 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
BR0111530A (pt) 2000-06-07 2003-07-22 Ortho Mcneil Pharm Inc Processo para detectar modulação de domìnio cinase de vegf
JP2005508298A (ja) * 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (de) * 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
GB0206072D0 (en) * 2002-03-15 2002-04-24 Astrazeneca Ab Epitope
ES2327040T3 (es) 2002-09-12 2009-10-23 Oncotherapy Science, Inc. Peptidos kdr y vacunas que los contienen.
CA2512624A1 (en) * 2003-01-29 2004-08-19 Merck & Co., Inc. Rat receptor tyrosine kinase, kdr
SI2949658T1 (sl) 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
WO2006120762A1 (ja) * 2005-05-11 2006-11-16 Murata Manufacturing Co., Ltd. アンテナ構造およびそれを備えた無線通信機
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
WO2013074814A2 (en) * 2011-11-15 2013-05-23 University Of Utah Research Fourdation Morpholinos, morpholino upregulating, and associated methods
US9506069B2 (en) 2012-04-19 2016-11-29 University Of Utah Research Foundation Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2083401C (en) * 1991-02-22 2003-03-25 Bruce I. Terman Identification of a novel human receptor tyrosine kinase gene
CA2064331C (en) 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis

Also Published As

Publication number Publication date
US20030032160A1 (en) 2003-02-13
WO1998058053A1 (en) 1998-12-23
EP1009814B1 (de) 2007-08-29
EP1009814A1 (de) 2000-06-21
US20030055239A1 (en) 2003-03-20
DE69838334T2 (de) 2008-06-12
US6841382B2 (en) 2005-01-11
US6359115B1 (en) 2002-03-19
US6204011B1 (en) 2001-03-20
CA2293723A1 (en) 1998-12-23
ES2292204T3 (es) 2008-03-01
US6841367B2 (en) 2005-01-11
JP4405597B2 (ja) 2010-01-27
EP1009814A4 (de) 2001-12-12
JP2002507119A (ja) 2002-03-05
ATE371727T1 (de) 2007-09-15
WO1998058053A9 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
ATE371727T1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
WO1999055868A3 (en) Fizz proteins
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
EP1464706A3 (de) HEK5, HEK7, HEK8, HEK11, EPH-ähnliche Protein-Tyrosinkinase-Rezeptoren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK1129190T3 (da) Human TSLP DNA og polypeptider
ATE541930T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DK0961831T3 (da) Humant alfa-endokin
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DE69728897D1 (de) Saeugetierchemokine
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
WO1998025957A3 (en) Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes
WO2004070004A3 (en) Rat receptor tyrosine kinase, kdr
NZ510812A (en) Novel peptides
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
WO2001057086A3 (en) Novel human g protein coupled receptor proteins and polynucleotides encoding the same
ATE492640T1 (de) Loslösendes protein 5 - ucp5
WO2002077190A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002016435A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2002061062A3 (en) Human protein kinase n-like polypeptide and uses thereof
DE60237236D1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation